Acceleration of bone-marrow recovery by pre-treatment with cyclophosphamide in patients receiving high-dose melphalan.
7 patients with advanced malignant melanoma who were given cyclophosphamide (500 mg intravenously) 7 days before a high dose of melphalan (140 mg/m2) had a more rapid recovery of the peripheral white-cell count than did 4 patients who received melphalan alone. "Priming" by cyclophosphamide might be a practicable means of offsetting the bone-marrow toxicity of some chemotherapy regimens and it may permit higher doses of drugs to be given safely.
D001812:Blood-Brain Barrier / Q000187:drug effects; D001853:Bone Marrow / Q000187:drug effects*; D001859:Bone Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000633:toxicity; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D007275:Injections, Intravenous; D007958:Leukocyte Count; D007962:Leukocytes / Q000187:drug effects; D008545:Melanoma / Q000188:drug therapy*; D008558:Melphalan / Q000008:administration & dosage* / Q000633:toxicity; D009362:Neoplasm Metastasis; D011292:Premedication; D012878:Skin Neoplasms / Q000188:drug therapy*
D003520:Cyclophosphamide; D008558:Melphalan